Comprehensive non-clinical respiratory evaluation of promising new drugs

Journal Article · Thu Sep 01 00:00:00 EDT 2005 · Toxicology and Applied Pharmacology

DOI:https://doi.org/10.1016/j.taap.2005.01.041· OSTI ID:20721939

Murphy, Dennis J ^[1]

---

1. Department of Safety Pharmacology, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406 (United States)

The need to evaluate the potential for new drugs to produce adverse effects on respiratory function in non-clinical safety assessment is based on the known effects of drugs from a variety of pharmacological/therapeutic classes on the respiratory system, the life-threatening consequences of respiratory dysfunction, and compliance with world-wide regulatory safety guidelines. The objective of this article is to provide a brief overview of the functional disorders of the respiratory system and to present the strategy and techniques considered to be most appropriate for detecting and characterizing drug-induced respiratory disorders in non-clinical safety studies.

• OSTI ID: 20721939
• Journal Information: Toxicology and Applied Pharmacology, Vol. 207, Issue 2,suppl.1; Conference: ICT X 2004: 10. international congress of toxicology: Living in a safe chemical world, Tampere (Finland), 11-15 Jul 2004; Other Information: DOI: 10.1016/j.taap.2005.01.041; PII: S0041-008X(05)00308-X; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0041-008X
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
COMPLIANCE
DRUGS
EVALUATION
RECOMMENDATIONS
RESPIRATORY SYSTEM
RISK ASSESSMENT
SAFETY
SAFETY ANALYSIS